How have AVCTF shares performed in 2024?

Avacta Group's stock was trading at $1.62 on January 1st, 2024. Since then, AVCTF stock has decreased by 63.5% and is now trading at $0.5906. View the best growth stocks for 2024 here .

How do I buy shares of Avacta Group?

Shares of AVCTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:AVCTF

Avacta Group (AVCTF) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free AVCTF Stock Alerts

$0.59

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.59
▼
$0.59
50-Day Range: $0.59
▼
$1.62
52-Week Range: $0.59
▼
$2.17

Volume: N/A
Average Volume: 3,217 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Short Interest

Get Avacta Group alerts:

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Avacta Group Stock (OTCMKTS:AVCTF)

Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

AVCTF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVCTF Stock News Headlines

April 5, 2024 | finance.yahoo.com

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

April 4, 2024 | morningstar.com

Avacta Group PLC AVCTF

April 16, 2024 | Traders Agency (Ad)

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

November 11, 2023 | morningstar.com

Avacta Group PLC AVCT

November 8, 2023 | finance.yahoo.com

Avacta Group's (LON:AVCT) growing losses don't faze investors as the stock soars 11% this past week

October 5, 2023 | finance.yahoo.com

Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 7, 2023 | finance.yahoo.com

Avacta Group Plc (LON:AVCT) is largely controlled by institutional shareholders who own 53% of the company

June 5, 2023 | lse.co.uk

Avacta sees shares rise on new equity payment for South Korea venture

April 16, 2024 | Traders Agency (Ad)

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

June 1, 2023 | finance.yahoo.com

Avacta Group's (LON:AVCT) investors will be pleased with their solid 218% return over the last five years

May 5, 2023 | finance.yahoo.com

Avacta Group Plc's (LON:AVCT) Business Is Trailing The Industry But Its Shares Aren't

April 7, 2023 | marketwatch.com

Avacta Group's Shares Rise on US Site Openings for Cancer Study Patient Enrolment

April 6, 2023 | lse.co.uk

Avacta doses first patient in fifth cohort of AVA6000 phase 1 study

April 6, 2023 | lse.co.uk

Avacta opens first two clinical investigator sites in US for AVA6000

April 5, 2023 | finance.yahoo.com

Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study

April 1, 2023 | finance.yahoo.com

Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting

March 31, 2023 | finanznachrichten.de

Avacta Group plc: Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division

March 31, 2023 | finance.yahoo.com

Avacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 55% of the company

January 17, 2023 | benzinga.com

Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

December 1, 2022 | finance.yahoo.com

Investors in Avacta Group (LON:AVCT) have made a incredible return of 538% over the past three years

September 11, 2022 | fool.co.uk

Avacta Group

September 5, 2022 | finance.yahoo.com

Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration

September 1, 2022 | finance.yahoo.com

Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort

May 3, 2022 | finance.yahoo.com

Even though Avacta Group (LON:AVCT) has lost UK£39m market cap in last 7 days, shareholders are still up 304% over 3 years

April 13, 2022 | finance.yahoo.com

Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake

January 18, 2022 | finance.yahoo.com

What You Need To Know About Avacta Group Plc's (LON:AVCT) Investor Composition

November 29, 2021 | finance.yahoo.com

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

See More Headlines

Receive AVCTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:AVCTF
CUSIP: N/A
CIK: N/A
Web: www.avacta.com
Phone: 44.1904.21.7070
Fax: N/A
Employees: 120
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. David Alastair Maclaughlin Smith (Age 58)
CEO & Executive Director
Comp: $560.66k
Mr. Tony Gardiner (Age 53)
CFO, Company Secretary & Executive Director
Comp: $344.73k
Dr. Christina Marie Coughlin B.S. (Age 54)
M.D., Ph.D., Head of Research & Development, Interim Chief Medical Officer and Director
Comp: $46.72k
Ms. Emma Wright
Group In-House Counsel
Mr. Michael Vinegrad
Group Communications Director
Mr. R. Craig Slater FCA (Age 60)
Chief Operating Officer of Diagnostics
Comp: $87.13k
Dr. Matt Johnson
Chief Scientific Officer of Diagnostics
Dr. Fiona McLaughlin FSB (Age 54)
Ph.D., Chief Scientific Officer of Therapeutics Division
Mr. David Wilson
Chief Commercial Officer of Diagnostics
Ms. Karen Harrison
Chief Operating Officer of Therapeutics Division

Key Competitors

View All Competitors

AVCTF Stock Analysis - Frequently Asked Questions

How have AVCTF shares performed in 2024?: Avacta Group's stock was trading at $1.62 on January 1st, 2024. Since then, AVCTF stock has decreased by 63.5% and is now trading at $0.5906.
View the best growth stocks for 2024 here.
How do I buy shares of Avacta Group?: Shares of AVCTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:AVCTF) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial